SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest long-term Week 40 Phase 3 data, which demonstrates deepening clinical efficacy and reinforces the company's best-in-class potential for treating Hidradenitis Suppurativa. The community is actively discussing the drug's regulatory pathway toward a BLA submission and the potential for a strategic buyout, while simultaneously debating market maker activity and recent analyst upgrades that have significantly raised price targets.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following a series of significant Department of Defense and defense-contractor awards, which have sparked intense community debate over the company's long-term production scalability and balance sheet health. While bulls point to these mission-critical manufacturing contracts as validation of the company's technology, short-sellers and skeptical investors remain focused on ongoing cash burn concerns and the potential for future equity dilution.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is facing intense volatility as shareholders grapple with the end of a major lock-up period and skepticism following a disappointing earnings report that revealed a lack of near-term tenant revenue. The community is sharply divided, with some investors aggressively calling for leadership changes and reporting the firm to the SEC, while others view the current price drop as a strategic buying opportunity in anticipation of future data center power demand.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors gear up for the upcoming fiscal year-end and 10-K filing, with the community highly focused on QNX revenue growth, backlog expansion, and the impact of the new Alloy Kore platform. Shareholders are actively debating management's guidance and the potential for a long-awaited breakout as they look for concrete signs of sustainable double-digit growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors weigh strong AI licensing potential and institutional backing against lingering concerns over platform monetization and data integrity. While community members debate whether the stock is a long-term growth play or currently oversold, high-profile litigation updates regarding content scraping continue to fuel active discussion about the company's valuation.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following positive trial data from its TETON-1 study, which demonstrated that nebulized Tyvaso significantly preserves lung function in patients with idiopathic pulmonary fibrosis. The community is actively discussing the potential for a major label expansion that could triple the addressable market for the therapy, leading to multiple analyst price target increases as the company prepares for an FDA submission.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is seeing heightened trading activity as the company's recent operational updates and offtake agreements drive significant investor interest, leading to strong buying momentum in the stock. The community is actively debating the stock's potential for a breakout, with many discussing the impact of lithium supply-demand dynamics and monitoring insider buying as a key indicator of confidence in future growth.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as the community debates its future following a major strategic shift to discontinue its Aortic Valve Systems, which has sparked discussions about potential impact on long-term margins and resource allocation. Meanwhile, investors are closely monitoring the stock's resilient momentum and recent bullish analyst outlooks that emphasize strong growth in the company's cardiovascular and electrophysiology segments.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community leans into its roots as a foundational internet meme, bolstered by the restoration of its original RageBuilder and Ragemaker tools. Enthusiasts are actively rallying around the project as a long-term culture play, emphasizing organic growth and community-driven content production as they target long-term valuation milestones.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing significant downward pressure following the release of phase 3 clinical trial data for its thyroid eye disease drug, elegrobart, which failed to demonstrate the level of efficacy compared to IV-based treatments that investors had hoped for. While management emphasizes the drug's safety profile and ongoing clinical progress, market participants are actively debating the competitive threat from established standards of care and potential future rivals, leading to increased volatility and a sharp decline in share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nyxoah SA (NASDAQ:NYXH) Receives Consensus Rating of "Moderate Buy" from Brokerages

Nyxoah SA (NASDAQ:NYXH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has...

Nyxoah's (NYXH) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated an "overweight" rating and set a $11.00 price objective on shares of Nyxoah in a research report on Monday...

Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at Oppenheimer MedTech Conference 2026

Nyxoah (NASDAQ:NYXH) used its presentation at Oppenheimer's MedTech and Services Conference 2026 to outline the company's early U.S. launch progress for its Genio system, a neuromodulation therapy...

Stifel Nicolaus Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price

Stifel Nicolaus lowered their price target on Nyxoah from $11.00 to $10.00 and set a "buy" rating for the company in a report on Friday...

Nyxoah (NASDAQ:NYXH) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Nyxoah (NASDAQ:NYXH - Get Free Report) posted its earnings results on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.04). The company had revenue of $6.62 million for the quarter, compared to analyst estimates...

Nyxoah (NYXH) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Nyxoah Q4 Earnings Call Highlights

Nyxoah (NASDAQ:NYXH) used its fourth-quarter and full-year 2025 earnings call to outline the first results from the U.S. launch of its Genio hypoglossal nerve stimulation system, discuss the evolving reimbursement environment for the category, and provide initial growth expectations for early 2026...

Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates

Nyxoah (NYXH) delivered earnings and revenue surprises of -4.62% and -2.46%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

KORU Medical Systems, Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates

KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of +50.00% and +0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah SA (NASDAQ:NYXH) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Nyxoah SA (NASDAQ:NYXH - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One...

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah SA

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

NYXH
Nyxoah SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NYXH News

NYXHNyxoah SA